A new CRISPR startup is betting regulators will ease up on gene-editing

Key scientist from Baby KJ team launches startup to scale personalized CRISPR medicines

Aurora Therapeutics, led by researcher Fyodor Urnov and venture capitalist Johnny Hu, is latest entry in the growing field of personalized CRISPR medicines.

Crispr Pioneer Launches Startup to Make Tailored Gene-Editing Treatments

Aurora Therapeutics, cofounded by Nobel Prize–winning scientist Jennifer Doudna, plans to use gene editing and a new FDA regulatory pathway to commercialize treatments for rare diseases.

Aurora sets out to capitalize on FDA’s new framework for bespoke drug therapies

Co-founded by Jennifer Doudna and Fyodor Urnov, the company intends to simultaneously develop many gene editing treatments for rare conditions by using the agency’s “plausible mechanism” pathway.

A new CRISPR startup is betting regulators will ease up on gene-editing

Here at MIT Technology Review we’ve been writing about the gene-editing technology CRISPR since 2013, calling it the biggest biotech breakthrough of the century. Yet so far, there’s been only one gene-editing drug approved. It’s been used commercially on only about 40 patients, all with sickle-cell disease. It’s becoming clear that the impact of CRISPR isn’t as big as we all hoped. In fact, there’s a pall of discouragement over the entire field—…

Aurora: Developing Therapies for the Millions of Patients with Rare Diseases

Johnny began his Ph.D. evolving new Cas9 enzymes in 2012, the same year that Jennifer Doudna published her seminal paper unveiling CRISPR as a revolutionary tool for gene editing and for which she would win her Nobel Prize in 2020. In the time since, we’ve seen immense progress in correcting genetic mutations in humans with remarkable clinical efficacy and the potential for one-time cures. However, the number of patients and diseases treated by …